Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance

Go back to Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance

Tandem Diabetes (TNDM) Q4 Sales Beat

February 22, 2022 4:14 PM EST

Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.16, which may not compare to the analyst estimate of $0.21. Revenue for the quarter came in at $210 million versus the consensus estimate of $198.39 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $845-860 million, versus... More